Andrey Lisitsa (Academician of the Russian Academy of Sciences), Alexander Lavrov (the Russian Research Centre of Medical Genetics), Nikolay Sergeev (CTO of a startup), XueLiang (CTO of Yaneng Bio), Yang Haitao (Chairman of Zhuhai Biocode), LiJingxiang(Executive Director of Strategic Investment Center of BGI Group).
In the guest roundtable forum under the theme of “Microfluidic Biochip Development Status and Application Market Prospects” and “Genetic Sequencing Clinical Application Status and Future Development Trends” hosted by Dr. He Yun of Axbio, six industry experts held exciting discussion around these topics. Dr. Xue Liang, CTO of YanengBio, said that the application of microfluidic chips includes digital PCR and NGS, microbes, etc. The main advantages are reflected in the low dosage of reagents, automation, high throughput, and full closure to avoid sample contamination. There are still many applications that can be developed. It is believed that the CMOS chip of Axbio will have a very broad application scope. Mr. Li Jingxiang, Executive Director of Strategic Investment Center of BGI Group, said that sequencing in China is strictly regulated from research and development to clinical practice, and a large amount of clinical sample data needs to be accumulated. If the cost of sequencing can be greatly reduced, it will definitely lead to broader clinical applications. Dr. Yang Haitao,Chairman of Zhuhai Biocode, mentioned that microfluidics has many clinical application scenarios, and the market for POCT detection kits for different diseases is huge. Dr. Lavrov pointed out that long-length long sequencing is more suitable for the field of CNV and analysis of complex structural variations. In addition to clinical applications, the sequencing platform of Axbio can be applied to environmental, microbial and animal and plant research.
Up to now, Axbio’s smart biochips are world-leading platform and can be widely used in whole genome sequencing, targeted sequencing, RNA sequencing, epigenetics, metagenomics, etc. It can also be applied to the detection of proteins, microorganisms, and toxic compounds, and greatly improves the existing detection throughput. In the future, with the latestAXP100 gene sequencer and smart biochip technology, Axbio will unveil themystery of genetic information and provide a powerful tool for the rapid development of precision medicine.
